134 related articles for article (PubMed ID: 12686851)
1. p53 immunopositivity in histologically favorable Wilms tumor is not related to stage at presentation or to biological aggression.
D'Angelo MF; Kausik SJ; Sebo TJ; Rathbun SR; Kramer SA; Husmann DA
J Urol; 2003 May; 169(5):1815-7. PubMed ID: 12686851
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.
Lahoti C; Thorner P; Malkin D; Yeger H
Am J Pathol; 1996 May; 148(5):1577-89. PubMed ID: 8623926
[TBL] [Abstract][Full Text] [Related]
3. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
4. p53 Immunohistochemistry expression in Wilms tumor: a prognostic tool in the detection of tumor aggressiveness.
Franken J; Lerut E; Van Poppel H; Bogaert G
J Urol; 2013 Feb; 189(2):664-70. PubMed ID: 23036984
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcome of Wilms tumors with a favorable histology in Japan: a report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan.
Suita S; Kinoshita Y; Tajiri T; Hara T; Tsuneyoshi M; Mizote H; Inada H; Takamatsu H; Kawano Y; Inomata Y; Nagasaki A; Ono Y; Handa N; Okamura J; Ishii E; Kawakami K;
J Pediatr Surg; 2006 Sep; 41(9):1501-5. PubMed ID: 16952581
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic sarcoma of the kidney: a clinicopathologic study of 20 cases of a new entity with polyphenotypic features.
Vujanić GM; Kelsey A; Perlman EJ; Sandstedt B; Beckwith JB
Am J Surg Pathol; 2007 Oct; 31(10):1459-68. PubMed ID: 17895746
[TBL] [Abstract][Full Text] [Related]
7. p53 expression in Wilms' tumor: a possible role as prognostic factor.
Beniers AJ; Efferth T; Füzesi L; Granzen B; Mertens R; Jakse G
Int J Oncol; 2001 Jan; 18(1):133-9. PubMed ID: 11115550
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of p53 protein expression as a prognostic factor in Wilms tumor.
Jadali F; Sayadpour D; Rakhshan M; Karimi A; Rouzrokh M; Shamsian BS; Shamshiri AR
Iran J Kidney Dis; 2011 Jul; 5(3):149-53. PubMed ID: 21525573
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of p53 expression in Wilms' tumor in children.
Skotnicka-Klonowicz G; Kobos J; Łoś E; Trejster E; Szymik-Kontorowicz S; Daszkiewicz P
Med Sci Monit; 2001; 7(6):1224-9. PubMed ID: 11687734
[TBL] [Abstract][Full Text] [Related]
10. Nephroblastoma: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells.
Camassei FD; Arancia G; Cianfriglia M; Bosman C; Francalanci P; Ravà L; Jenkner A; Donfrancesco A; Boldrini R
Am J Clin Pathol; 2002 Mar; 117(3):484-90. PubMed ID: 11888090
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
[TBL] [Abstract][Full Text] [Related]
12. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes in adults with favorable histologic type Wilms tumor-an update from the National Wilms Tumor Study Group.
Kalapurakal JA; Nan B; Norkool P; Coppes M; Perlman E; Beckwith B; Ritchey M; Breslow N; Grundy P; D'angio GJ; Green DM; Thomas PR
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1379-84. PubMed ID: 15590168
[TBL] [Abstract][Full Text] [Related]
14. Expression and prognostic value Of CD44 isoforms in nephroblastoma (Wilms tumor).
Ghanem MA; Van Steenbrugge GJ; Van Der Kwast TH; Sudaryo MK; Noordzij MA; Nijman RJ
J Urol; 2002 Aug; 168(2):681-6. PubMed ID: 12131349
[TBL] [Abstract][Full Text] [Related]
15. Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
Basta-Jovanović G; Radonjic V; Stolic I; Nenadovic M; Brasanac D; Jovanovic D; Radojevic-Skodric S
Ren Fail; 2005; 27(1):13-8. PubMed ID: 15717629
[TBL] [Abstract][Full Text] [Related]
16. B7-h1 as a biomarker for therapy failure in patients with favorable histology Wilms tumor.
Routh JC; Grundy PE; Anderson JR; Retik AB; Kurek KC
J Urol; 2013 Apr; 189(4):1487-92. PubMed ID: 23154206
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein expression, tumor weight, age, and relapse in patients with stage I and II favorable-histology Wilms' tumor.
Teixeira RA; Odone-Filho V; de Camargo B; Zerbini MC; Fillipi R; Alencar A; Cristofani L
Pediatr Hematol Oncol; 2011 Apr; 28(3):194-202. PubMed ID: 21214406
[TBL] [Abstract][Full Text] [Related]
18. Wilms' tumor at the Children's Hospital of Eastern Ontario: 1990-2001.
Pianezza ML; Rubin S; Bass J; Chou S; Pike JG; Leonard MP
Can J Urol; 2004 Feb; 11(1):2151-6. PubMed ID: 15003157
[TBL] [Abstract][Full Text] [Related]
19. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
Dome JS; Cotton CA; Perlman EJ; Breslow NE; Kalapurakal JA; Ritchey ML; Grundy PE; Malogolowkin M; Beckwith JB; Shamberger RC; Haase GM; Coppes MJ; Coccia P; Kletzel M; Weetman RM; Donaldson M; Macklis RM; Green DM
J Clin Oncol; 2006 May; 24(15):2352-8. PubMed ID: 16710034
[TBL] [Abstract][Full Text] [Related]
20. [Expression of Stat3, HIF-1alpha and VEGF in Wilms' tumor].
Niu ZB; Wang CL; Hou Y; Yang Y; Gao H
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Oct; 9(5):461-4. PubMed ID: 17937859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
